We are live on ! Find out more
EAM

Eventide Asset Management Portfolio holdings

AUM $6.05B
1-Year Est. Return 76.64%
This Fund
S&P 500
This Quarter Est. Return
+2.03%
1 Year Est. Return
+76.64%
3 Year Est. Return
+247.17%
5 Year Est. Return
+285.6%
10 Year Est. Return
+2,546.71%
AUM
$6.75B
AUM Growth
+$227M
Cap. Flow
+$450M
Cap. Flow %
6.66%
Top 10 Hldgs %
24.03%
Holding
181
New
21
Increased
67
Reduced
21
Closed
25

Top Buys

Rank Stock Value
1
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
+$76.7M
2
ZYME icon
Zymeworks
ZYME
+$56.8M
3
ENTG icon
Entegris
ENTG
+$55.4M
4
TSM icon
TSMC
TSM
+$52.9M
5
CGEM icon
Cullinan Oncology
CGEM
+$49.2M

Top Sells

Rank Stock Value
1
ECL icon
Ecolab
ECL
+$49.8M
2
W icon
Wayfair
W
+$45.9M
3
EIDX
Eidos Therapeutics, Inc. Common Stock
EIDX
+$41.8M
4
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$23.8M
5
CRWD icon
CrowdStrike
CRWD
+$23.5M

Sector Composition

Rank Sector Weight
1 Healthcare 40.16%
2 Technology 26.2%
3 Industrials 11.22%
4 Consumer Discretionary 7.43%
5 Communication Services 4.9%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PANW icon
51
Palo Alto Networks
PANW
$265B
$48.1M 0.71%
895,422
+4,284
+0.5% +$255K
TPTX
52
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
$47.8M 0.71%
505,000
-78,000
-13% -$9.28M
NBIX icon
53
Neurocrine Biosciences
NBIX
$18.7B
$46.1M 0.68%
474,000
+121,000
+34% +$12.7M
BEPC icon
54
Brookfield Renewable
BEPC
$6.04B
$45.8M 0.68%
978,357
+510,957
+109% +$26.1M
KURA icon
55
Kura Oncology
KURA
$826M
$45.7M 0.68%
1,617,573
+557,573
+53% +$17.6M
SNDX icon
56
Syndax Pharmaceuticals
SNDX
$1.73B
$45.1M 0.67%
2,016,993
+70,993
+4% +$1.6M
BPMC
57
DELISTED
Blueprint Medicines
BPMC
$44.9M 0.67%
462,000
– –
ZYME icon
58
Zymeworks
ZYME
$1.67B
$44.1M 0.65%
+1,397,954
New +$56.8M
BBIO icon
59
BridgeBio Pharma
BBIO
$16.1B
$43.9M 0.65%
+712,197
New +$46.6M
CLDX icon
60
Celldex Therapeutics
CLDX
$3.02B
$42.5M 0.63%
2,062,433
+225,325
+12% +$5.17M
IMVT icon
61
Immunovant
IMVT
$8.11B
$39.7M 0.59%
2,473,000
+1,541,000
+165% +$40.6M
HASI icon
62
Hannon Armstrong Sustainable Infrastructure Capital
HASI
$4.85B
$39.3M 0.58%
700,200
-132,000
-16% -$7.94M
DDOG icon
63
Datadog
DDOG
$95.6B
$39.2M 0.58%
470,903
+3,500
+0.7% +$337K
NRIX icon
64
Nurix Therapeutics
NRIX
$2.45B
$37.3M 0.55%
1,200,000
+150,000
+14% +$5.68M
NOVT icon
65
Novanta
NOVT
$4.95B
$36.9M 0.55%
280,000
– –
CWEN icon
66
Clearway Energy Class C
CWEN
$4.94B
$36.7M 0.54%
1,303,400
+56,100
+4% +$1.72M
MAX icon
67
MediaAlpha
MAX
$732M
$36.7M 0.54%
1,034,559
+972,948
+1,579% +$48.2M
ALLK
68
DELISTED
Allakos
ALLK
$36.4M 0.54%
317,000
– –
ZNTL icon
69
Zentalis Pharmaceuticals
ZNTL
$350M
$36.1M 0.54%
832,000
– –
KALV
70
DELISTED
KalVista Pharmaceuticals
KALV
$35.3M 0.52%
1,373,000
-307,000
-18% -$8.07M
VCYT icon
71
Veracyte
VCYT
$4.77B
$35M 0.52%
651,000
-279,000
-30% -$16.1M
ETNB
72
DELISTED
89bio
ETNB
$30M 0.45%
1,268,539
+399,539
+46% +$9.22M
FRLN
73
DELISTED
Freeline Therapeutics Holdings plc American Depositary Shares
FRLN
$29.8M 0.44%
165,710
– –
CGNX icon
74
Cognex
CGNX
$10.4B
$29.8M 0.44%
359,000
– –
LII icon
75
Lennox International
LII
$14.5B
$29.6M 0.44%
95,000
– –
1 2
3
4 5

Similar funds

HPG
Harvest Portfolios Group Oakville, Ontario, Canada $6.06B AUM 16.63% 1-Year Est. Return
EMPI
Elo Mutual Pension Insurance Espoo, Finland $6.06B AUM 24.33% 1-Year Est. Return
RCG
Ruane, Cunniff & Goldfarb New York $6.03B AUM 12.06% 1-Year Est. Return
JWBC
John W. Bristol & Co New York $6.08B AUM 16.51% 1-Year Est. Return
AAM
Advisors Asset Management Monument, Colorado $6.01B AUM 24.74% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
CM
CastleKnight Management New York $6B AUM 121.87% 1-Year Est. Return
CIS
Capital International Sarl Los Angeles, California $6.11B AUM 32.29% 1-Year Est. Return

Eventide Asset Management's Q1 2021 Portfolio in Review

As of Q1 2021, Eventide Asset Management held 181 positions worth $6.75B, up 3.5% from $6.52B the previous quarter. Its ten largest holdings account for 24% of the portfolio.

Eventide Asset Management deployed $450M of net new capital in Q1 2021, opening 21 new positions and adding to 67 existing holdings. Its largest new stake was Prometheus Biosciences, Inc. Common Stock: 3,714,032 shares worth $65.6M.

By sector, the portfolio is most concentrated in Healthcare at 40% of assets, down from 42% a quarter earlier, followed by Technology and Industrials.

On the sell side, the largest reduction was Wayfair, an estimated $45.9M trimmed.

  • Eventide Asset Management's largest Q1 2021 buy was Prometheus Biosciences, Inc. Common Stock: 3,714,032 shares worth $65.6M.
  • Eventide Asset Management added most to Entegris in Q1 2021, an estimated $55.4M increase.
  • Eventide Asset Management's biggest Q1 2021 reduction was Wayfair, cutting an estimated $45.9M.
  • Eventide Asset Management fully exited Ecolab in Q1 2021, selling an estimated $49.8M.
  • Eventide Asset Management's ten largest holdings make up 24% of its $6.75B portfolio in Q1 2021.
  • Eventide Asset Management opened 21 new positions and closed 25 in Q1 2021.
  • Eventide Asset Management's portfolio value rose 3.5% quarter-over-quarter to $6.75B.

Based on Eventide Asset Management's 13F filing for Q1 2021, filed 14 May 2021.